Menu
Search
|

Menu

Close
X

Natera Inc NTRA.OQ (NASDAQ Stock Exchange Global Select Market)

20.30 USD
-- (--)
As of Mar 20
chart
Previous Close 20.30
Open --
Volume --
3m Avg Volume 238,684
Today’s High --
Today’s Low --
52 Week High 29.53
52 Week Low 8.60
Shares Outstanding (mil) 62.79
Market Capitalization (mil) 1,274.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
258
FY17
210
FY16
217
EPS (USD)
FY18
-2.230
FY17
-2.579
FY16
-1.846
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
4.95
8.99
Price to Book (MRQ)
vs sector
39.19
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
384.02
17.49
LT Debt to Equity (MRQ)
vs sector
228.09
13.83
Return on Investment (TTM)
vs sector
-97.37
12.11
Return on Equity (TTM)
vs sector
-445.14
13.22

EXECUTIVE LEADERSHIP

Matthew Rabinowitz
Chairman of the Board, President, Co-Founder, Since 2019
Salary: $505,443.00
Bonus: --
Steven Chapman
Chief Executive Officer, Since 2019
Salary: $368,616.00
Bonus: --
Jonathan Sheena
Co-Founder, Chief Technology Officer, Director, Since 2007
Salary: $321,000.00
Bonus: --
Michael Brophy
Chief Financial Officer, Since 2017
Salary: $329,848.00
Bonus: --
Robert Schueren
Chief Operating Officer, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

201 Industrial Rd Ste 410
SAN CARLOS   CA   94070-2396

Phone: +1650.2499090

Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).

SPONSORED STORIES